ArticleNature communications2021
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Plasma histone monomers as novel diagnostic markers in adult glioblastoma.The journal of liquid biopsy · 2026Article
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- Prognostic relevance and cytokine correlates of peripheral immune subpopulations in newly diagnosed glioblastoma.Journal of neuro-oncology · 2026Article
- Childhood brain tumors instruct cranial hematopoiesis and immunotolerance.Nature genetics · 2026Article
- Insights into FACT in Cancers with Targeted Therapeutic Implications.Molecular and cellular biology · 2026Review
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
- Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.Signal transduction and targeted therapy · 2025Article
- Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy.iScience · 2025Article
- Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care.Diagnostics (Basel, Switzerland) · 2025Review
- Deciphering cancer complexity: perspective on hematopoietic remodeling-mediated immunosuppression.Oncogene · 2025Review
- Single-cell transcriptomic analysis reveals prognosis-related stromal signatures that potentiate stratification of patients with extrahepatic cholangiocarcinoma.BMC gastroenterology · 2025Article
- Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma.Journal of translational medicine · 2025Article
- Unraveling Glioblastoma: TME Implication and Gene Therapy Advances.Current gene therapy · 2025Review
- Cranioencephalic functional lymphoid units in glioblastoma.Nature medicine · 2024Article
- Understanding glioblastoma at the single-cell level: Recent advances and future challenges.PLoS biology · 2024Article
- Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice.Cell death & disease · 2024Article
- Extramedullary hematopoiesis in cancer.Experimental & molecular medicine · 2024Review
- HArmonized single-cell RNA-seq Cell type Assisted Deconvolution (HASCAD).BMC medical genomics · 2023Article
- Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas.Diagnostics (Basel, Switzerland) · 2023Article
- Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors are typically immunosuppressive and refractory to immunotherapies for reasons that remain poorly understood. The unbiased profiling of immune cell types in the tumor microenvironment may reveal immunologic networks affecting therapy and course of disease. Here we identify and validate the presence of hematopoietic stem and progenitor cells (HSPCs) within glioblastoma tissues. Furthermore, we demonstrate a positive link of tumor-associated HSPCs with malignant and immunosuppressive phenotypes. Compared to the medullary hematopoietic compartment, tumor-associated HSPCs contain a higher fraction of immunophenotypically and transcriptomically immature, CD38- cells, such as hematopoietic stem cells and multipotent progenitors, express genes related to glioblastoma progression and display signatures of active cell cycle phases. When cultured ex vivo, tumor-associated HSPCs form myeloid colonies, suggesting potential in situ myelopoiesis. In experimental models, HSPCs promote tumor cell proliferation, expression of the immune checkpoint PD-L1 and secretion of tumor promoting cytokines such as IL-6, IL-8 and CCL2, indicating concomitant support of both malignancy and immunosuppression. In patients, the amount of tumor-associated HSPCs in tumor tissues is prognostic for patient survival and correlates with immunosuppressive phenotypes. These findings identify an important element in the complex landscape of glioblastoma that may serve as a target for brain tumor immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.